Muhammad Umair Mushtaq (Abu Mikael)
@mumairmushtaq
Followers
1,256
Following
1,295
Media
54
Statuses
272
Associate Professor Hematologic Malignancies & Cellular Therapeutics @KUMedCenter . Alumni @uwsmph @CookCountyIMR . All views are my own
Kansas City, KS
Joined April 2015
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Rafah
• 462518 Tweets
Xavi
• 324971 Tweets
Ten Hag
• 108830 Tweets
Memorial Day
• 80033 Tweets
سلمان
• 79763 Tweets
#تتويج_الهلال
• 78498 Tweets
QSMP
• 55117 Tweets
#LisbonTStheErasTour
• 47115 Tweets
Coutinho
• 44429 Tweets
Accidentally
• 32933 Tweets
Morgan Spurlock
• 32496 Tweets
Neto
• 32423 Tweets
Karoline
• 30064 Tweets
Gove
• 29939 Tweets
Militão
• 29385 Tweets
Ergin Ataman
• 29120 Tweets
Mourão
• 23049 Tweets
Cecília
• 20990 Tweets
Tyga
• 19721 Tweets
Datti
• 19350 Tweets
الدوري الاقوي
• 15653 Tweets
Guarani
• 15120 Tweets
نيمار
• 14979 Tweets
Girona
• 14633 Tweets
Granada
• 14259 Tweets
#OlympiacosBC
• 11645 Tweets
THE WAY I LOVED YOU
• 10606 Tweets
Sharks
• 10271 Tweets
Promoted as Associate Professor of Medicine at University of Kansas Medical Center, Division of Hematologic Malignancies & Cellular Therapeutics.
Alhamdulillah ya Rab al Alamin 😊
@KUcancercenter
@KUMedCenter
56
5
329
The Mikael Rayaan Foundation (MRF)
11
65
183
Inauguration of a state-of-the art pediatric tertiary care outpatient clinic in Lahore that will provide free care to millions of poor children from Punjab, humble beginnings
@jakramaimc
@saleemranjha
#MRF
#MikaelRayaanFoundation
3
17
149
University of Kansas Medical Center Division of Hematologic Malignancies and Cellular Therapeutics Clinical Research Excellence Award... Thankful to all my amazing colleagues for the nomination ☺️🙏 Alhamdulillah ❤️
8
2
120
Love of my life ♥️ Pure hearts, spreading light in Heavens and Earth…
#MRF
#MikaelRayaanFoundation
2
0
116
Insha’Allah, we will support free tertiary care treatment of poor children, in collaboration with Al-Rafea Foundation AAPKA clinic
@jakramaimc
@saleemranjha
#MRF
#MikaelRayaanFoundation
0
13
95
Humbled to receive the Karl and Irene Eisemann Award for Hematologic Malignancies and Cellular Therapeutics, in recognition of exceptional research and accompanied by a $3000 monetary prize
8
1
89
Doximity: Top 10% Most Cited Clinician; Top 10% Most Published Clinician; Clinical Trial Leader
Alhamdulillah ♥️
4
1
84
Today is Mikael’s birthday and we received excellent news. “The Mikael Rayaan Foundation” is now fully registered by IRS as a 501 (c)(3) public charity organization effective July 17, 2023.
هَلْ جَزَآءُ ٱلْإِحْسَٰنِ إِلَّا ٱلْإِحْسَٰنُ
#MRF
2
1
77
Sharing a remarkable story of perseverance at KU Morning Medical Updates show with my patient with acute leukemia who is cured by a bone marrow transplant from his son ♥️
3
1
75
Highly grateful for continued support from our amazing community… Introducing the Mikael Rayaan Foundation Kansas City! ♥️
3
1
60
Mandatory KU HMCT yellow team picture ♥️ American Society of Hematology Annual Meeting Review
@aksinghmd
@KUcancercenter
@KUMedCenter
@ASH_hematology
1
3
53
Humbled to receive Robert Korngold Award for Best Cellular Therapy Article
@ASTCT
#Tandem22
@KUcancercenter
@KUMedCenter
5
3
52
Good news! Our article received enough citations to be a
#TopCitedArticle
in the Transplant Infectious Disease journal.
1
0
49
The KUCC Bench to Bedside Podcast discussing newly FDA approved Tumor Infiltrating Lymphocytes (TIL) Cell Therapy in Metastatic Melanoma. I am humbled to be part of clinical trials for this groundbreaking work in treating cancers ♥️ Alhamdulillah
@KUcancercenter
@KUMedCenter
0
1
40
Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-mutated MDS
0
8
37
Proud to present the 2023 USMIRC Mikael Rayaan Award 🥇 Congratulations to our amazing team 🎉
0
1
36
We have envisioned, planned, and already working on several projects. We have estimated at least $250,000 for 5 years and about one-third will be supported by external donations
#MRF
#mikaelrayaanfoundation
2
3
34
Our article ranked in the top 10% of papers published
#TopDownloadedArticle
in Transplant Infectious Disease journal.
1
0
32
Hat trick 😉 third manuscript was published in the same week, a lot of work behind the scenes, just a co-incidence
@KUcancercenter
@KUMedCenter
@mumairmushtaq
@NausheenAhmedMD
@aksinghmd
2
2
32
Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation... Transplant Infectious Disease. 2024
@Abdallah81MD
@NausheenAhmedMD
@aksinghmd
@leshune
@polichka_md
@kashifaminMD
0
6
25
1
1
25
Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT).
0
8
24
First investigator-initiated cellular therapy trial...
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma.
0
1
22
Our amazing KU group at TCT closing reception
@NausheenAhmedMD
@kelseykonrardy
@MNelsonPharmD
@KUcancercenter
0
2
21
Bellman P … Mushtaq MU. Successful treatment with Fludarabine and Cyclophosphamide in a VEXAS syndrome patient with associated Myelodysplastic Syndrome: a case report and systemic review. Frontiers in Oncology. 2024; 14: 138373
1
3
17
0
1
15
@NausheenAhmedMD
First ever graft-versus-host disease (GVHD) day!
#Tandem2023
@KUcancercenter
1
3
15
We had several virtual posters, kudos to my fellow (virtual mentee)
@Siddhar17952122
who showed up for onsite poster all the way from Florida 😉
#tandem22
1
0
13
Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy 1/6900/505281/Outcomes-Multiple-Myeloma-Patients-Progressing
0
2
9
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review.
0
1
9
0
0
8
Phase I/II study evaluating safety and efficacy of allogeneic SMART101 T-lymphoid progenitor injection to accelerate immune reconstitution after T-cell depleted allogeneic HSCT
EHA Library; Jun 08 2023; 385851
0
0
8
Mushtaq et al. Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation. Leukemia & Lymphoma 2024
0
1
7
Introducing the Mikael Rayaan Foundation Kansas City Sunday November 5, 5.30 pm, please join us if you are in KC (9005 W 151st St, Overland Park, KS 66221)
1
1
7
Sharing a remarkable story of perseverance at KU Morning Medical Updates show with my patient with acute leukemia who is cured by a bone marrow transplant from his son ♥️
0
0
7
Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched U...
0
0
7
Al-Ramahi JS … Mushtaq MU. Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2023)
0
1
7
Rural communities and health professional shortage areas (HPSA) and access to immune effector cellular therapy and lymphoma/myeloma clinical trials.
1
1
6
Mushtaq, et al. Impact of SARS-CoV-2 in hematopoietic stem cell transplant and CAR-T cell therapy recipients. Transplantation and Cellular Therapy. 2021 (PMID: 34256172)
1
1
6
Correct go fund me link:
1
0
4
Outcomes with CD34 stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation for hematologic malignancies: A systemic review and meta-analysis.
1
1
3
Top 100 Cited Articles on Clinical Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis
0
1
4
Innate Killer Cell Summit 2023… cool science, from bench to bedside🤞
0
0
4
Impact of Natural Killer Cells on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
0
2
4
Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgr...
0
1
4
With the boss, very close to my heart!!
0
0
4
A Multicenter Experience: Duration of Mandatory CRS and Icans Monitori...
0
3
4
1
1
3
Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis
1
2
3
Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell...
0
1
3
Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell L...
0
1
3
Treads & Threads is the University of Kansas black-tie gala… fun and glamorous evening under the stars but at its heart is a party with a purpose: we have raised more than $17 million to help those living with cancer receive world-class patient care
@KUcancercenter
@KUMedCenter
0
0
3
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
0
0
3
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review
0
1
3
Risk Factors and Outcomes for Patients with Persistent Cytopenia Following Administration of CD19 CAR-T Cell Therapy in B Cell Lymphoma
0
3
3
Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review
0
0
3
Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple ...
0
2
2
The GLAMM1 Study - Global Access to Myeloma Medications: Potential Bar...
0
1
2
Chimeric Antigen Receptor T-Cell (CAR-T) Access Among Rural and Health...
0
1
2
Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric...
0
1
2
P1403: SI101-01 PHASE I/II STUDY EVALUATING SAFETY AND EFFICACY OF ALLOGENEIC SMART101 T-LYMPHOID PROGENITOR INJECTION ...
0
0
2
0
0
2
0
0
2
VD-PACE As Salvage and Bridging Therapy to Transplant and Cellular The...
0
2
2
Eltrombopag Stimulation for Neutrophil and Platelet Recovery Following Axicabtagene Ciloleucel (axi-cel) Therapy in Lymphoma 1/12757/490467/Eltrombopag-Stimulation-for-Neutrophil-and/
0
1
2
Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
0
1
2
Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CAR T) Therapy Access
0
1
2
BCMA Re-Emergence: Can It Serve As a Prognostic Biomarker in Multiple ...
0
1
2